المؤلفون: Petr Vachal (1445962), Joseph L. Duffy (1601548), Louis-Charles Campeau (1392772), Rupesh P. Amin (11256557), Kaushik Mitra (1445974), Beth Ann Murphy (1445965), Pengcheng P. Shao (1884841), Peter J. Sinclair (2193679), Feng Ye (173489), Revathi Katipally (11256560), Zhijian Lu (2193661), Debra Ondeyka (11256563), Yi-Heng Chen (2952183), Kake Zhao (1445980), Wanying Sun (1927315), Sriram Tyagarajan (1580329), Jianming Bao (2125180), Sheng-Ping Wang (1463758), Josee Cote (11256566), Concetta Lipardi (7905071), Daniel Metzger (363813), Dennis Leung (5987798), Georgy Hartmann (11256569), Gordon K. Wollenberg (11256572), Jian Liu (33711), Lushi Tan (1433473), Yingju Xu (1923742), Qinghao Chen (1367955), Guiquan Liu (2812297), Robert O. Blaustein (11256575), Douglas G. Johns (1445989)

مصطلحات موضوعية: Biochemistry, Medicine, Pharmacology, Cancer, Infectious Diseases, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, guide optimization informed, coronary heart disease, clinical outcomes trial, reduced chd risk, risk reduction, clinical evidence, vivo paradigms, statin ), represents one, present preclinical, key regulators, inhibitor backup, including high, density lipoprotein, critical understanding, class molecule

Relation: https://figshare.com/articles/dataset/Invention_of_MK-8262_a_Cholesteryl_Ester_Transfer_Protein_CETP_Inhibitor_Backup_to_Anacetrapib_with_Best-in-Class_Properties/15144548

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c00959.s001